

CLAIMS

1. An isolated anti-TREM-2 antibody comprising (a) a light chain variable region comprising an L1 of SEQ ID NO: 17, an L2 comprising the amino acid sequence KVS, and an L3 of SEQ ID NO: 18; and/or (b) a heavy chain variable region comprising an H1 of SEQ ID NO: 19, an H2 of SEQ ID NO: 19, and an H3 of SEQ ID NO: 20.
2. The isolated antibody of claim 1, wherein the amino acid sequence of the light chain variable region is SEQ ID NO: 15.
3. The isolated antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 16.
4. The isolated antibody of claim 1, wherein the amino acid sequence of the light chain variable region is SEQ ID NO: 15 and the amino acid sequence of the heavy chain variable region is SEQ ID NO: 16.
5. The isolated antibody of claims 1, wherein the framework region of each variable region that has at least 75% sequence identity with a human framework region sequence.
6. The isolated antibody of claim 1, wherein the isolated antibody further comprises one or more constant regions, or a portion of a constant region, that has at least 90% sequence identity with human constant region sequence.
7. The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody or an antibody fragment.
8. A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier or excipient.

9. The pharmaceutical composition of claim 8, further comprising a dispersing agent, buffer, surfactant, preservative, solubilizing agent, isotonicity agent, or stabilizing agent.
10. The pharmaceutical composition of claim 8, wherein said carrier comprises physiological saline, ion exchanger, alumina, aluminum stearate, lecithin, serum protein, human serum albumin, buffer, phosphate, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acids, water, salts or electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol, wool fat, or a combination thereof.
11. The isolated antibody of claim 1 for use in a method of treating at least one A β plaque-associated symptom or at least one CAA-associated symptom in a subject in need thereof, wherein a therapeutically effective amount of the anti-TREM-2 antibody is to be administered to the subject.
12. Use of the isolated antibody of claim 1 in the manufacture of a medicament for the treatment of at least one A β plaque-associated symptom or at least one CAA-associated symptom in a subject in need thereof, wherein a therapeutically effective amount of the anti-TREM-2 antibody is to be administered to the subject.
13. The isolated antibody for use according to claim 11, or the use according to claim 12, wherein the use includes preventing, attenuating, reversing, or improving at least one symptom or sign of A β plaque or at least one CAA associated symptom in a subject.
14. The isolated antibody for use, or the use according to claim 13, wherein the A β plaque-associated symptom or the CAA-associated symptom is selected from neuronal degeneration, impaired cognitive function, altered behavior, abnormal language function, emotional dysregulation, seizures, impaired nervous system

structure, impaired nervous system function, an increased risk of development of Alzheimer's disease, or an increased risk of development of cerebral amyloid angiopathy.

15. The isolated antibody for use according to claim 11, or the use according to claim 12, wherein the antibody is to be systemically administered.
16. The isolated antibody for use according to claim 11, or the use according to claim 12, wherein the antibody is to be locally administered, optionally directly within the central nervous system.
17. The isolated antibody for use according to claim 11, or the use according to claim 12, wherein (a) the framework region of each variable region of the antibody has at least 75% sequence identity with a human framework region sequence; (b) the antibody further comprises one or more constant regions, or a portion of a constant region, that has at least 90% sequence identity with human constant region sequence; (c) the antibody is a monoclonal antibody or an antibody fragment; or (d) any combination of (a) to (c).
18. The isolated antibody of claim 1 for use in a method of decreasing amyloid plaque load and/or CAA load in the brain of a subject in need thereof, wherein a therapeutically effective amount of at least one anti-TREM-2 antibody is to be administered to the subject, and wherein the antibody is an antibody of claim 1.
19. The isolated antibody for use according to claim 18, wherein the antibody is to be peripherally administered.
20. The isolated antibody for use according to claim 18, wherein the antibody is to be locally administered, optionally directly within the central nervous system.
21. The isolated antibody for use according to claim 18, wherein amyloid plaque load is decreased in the hippocampus or decreased in the cortex.

22. The isolated antibody for use according to claim 21, wherein CAA loads are decreased in the penetrating arterioles on the surface of the cerebral cortex and/or the leptomeningeal arterioles on the surface of the cerebral cortex.